A Step Toward Overcoming a Melanoma Drug Resistance Pathway
Source: Dermatology Times, February 2024
Researchers have identified an epigenetic pathway involved in resistance to mitogen-activated protein kinase inhibitors, pointing the way to better patient treatment for resistant melanomas.
A study conducted at the Boston University Chobanian & Avedisian School of Medicine investigating BRAF-mutant melanomas that develop resistance to mitogen-activated protein kinase (MAPK) inhibitors identified a critical pathway in the resistance phenomenon, as well as a chemical reagent that can resensitize therapy-resistant cancers to targeted therapies, according to the university.1
The study appeared online today in the Journal of Clinical Investigation.